Javascript must be enabled to continue!
Frailty as a predictor of adverse outcomes in burn patients: a systematic review
View through CrossRef
Abstract
Background
The identification of new prognostic tools for the prediction of burn patients’ morbidity outcomes is necessary. Considering the feasibility of frailty assessment in the clinical setting, we aim to systematically review the literature on the associations between frailty and adverse outcomes in burn patients.
Methods
Studies were retrieved from MEDLINE (through PubMed), Web of Science, Scopus, and Embase from their inception up to 8 September 2022. Included studies were those that used frailty indices to predict adverse outcomes in burn patients. The quality assessment was done using the National, Heart, Lung, and Blood Institute (NHLBI) checklist. The results were synthesized narratively.
Results
We included 18 studies. The sample size among the included studies varied between 42–1615 patients. There were 12 research articles and 6 conference abstracts. Most of the studies were recently published in 2021 and 2022. Seven different frailty measures were evaluated. The following frailty measures were used: Canadian Study for Health and Ageing (CSHA) Clinical Frailty score (CFS), Modified frailty index-11 (mFI-11), Hospital frailty index, FRAIL scale, Emergency General Surgery Frailty Index (EGSFI), and Burn frailty index (BFI). There was only one report regarding a specific frailty index designed for the burn population (BFI). Except for one study (which used mFI-11), all included studies have shown a significant effect between assessing frailty and predicting worse outcomes. The CFS was an independent predictor of mortality among the burn population with high certainty of evidence. We found a significant association for other frailty indices as a predictor of mortality, however, the certainty of evidence regarding those was not high. Eight studies found a positive association between assessing frailty and unfavorable discharge location. There was no association between frailty and increased length of stay.
Conclusion
In conclusion, the postadmission assessment of frailty can be a reliable tool for predicting unfavorable outcomes and mortalities among patients with burn injuries. In addition, future studies with various populations from other countries are required to evaluate the efficacy of frailty indices measurement in order to strengthen the available evidence.
Springer Science and Business Media LLC
Title: Frailty as a predictor of adverse outcomes in burn patients: a systematic review
Description:
Abstract
Background
The identification of new prognostic tools for the prediction of burn patients’ morbidity outcomes is necessary.
Considering the feasibility of frailty assessment in the clinical setting, we aim to systematically review the literature on the associations between frailty and adverse outcomes in burn patients.
Methods
Studies were retrieved from MEDLINE (through PubMed), Web of Science, Scopus, and Embase from their inception up to 8 September 2022.
Included studies were those that used frailty indices to predict adverse outcomes in burn patients.
The quality assessment was done using the National, Heart, Lung, and Blood Institute (NHLBI) checklist.
The results were synthesized narratively.
Results
We included 18 studies.
The sample size among the included studies varied between 42–1615 patients.
There were 12 research articles and 6 conference abstracts.
Most of the studies were recently published in 2021 and 2022.
Seven different frailty measures were evaluated.
The following frailty measures were used: Canadian Study for Health and Ageing (CSHA) Clinical Frailty score (CFS), Modified frailty index-11 (mFI-11), Hospital frailty index, FRAIL scale, Emergency General Surgery Frailty Index (EGSFI), and Burn frailty index (BFI).
There was only one report regarding a specific frailty index designed for the burn population (BFI).
Except for one study (which used mFI-11), all included studies have shown a significant effect between assessing frailty and predicting worse outcomes.
The CFS was an independent predictor of mortality among the burn population with high certainty of evidence.
We found a significant association for other frailty indices as a predictor of mortality, however, the certainty of evidence regarding those was not high.
Eight studies found a positive association between assessing frailty and unfavorable discharge location.
There was no association between frailty and increased length of stay.
Conclusion
In conclusion, the postadmission assessment of frailty can be a reliable tool for predicting unfavorable outcomes and mortalities among patients with burn injuries.
In addition, future studies with various populations from other countries are required to evaluate the efficacy of frailty indices measurement in order to strengthen the available evidence.
Related Results
[RETRACTED] Keto Burn Dx Your Way To Amazing Results v1
[RETRACTED] Keto Burn Dx Your Way To Amazing Results v1
[RETRACTED]Top Of The Line Keto Products: Cost Of Keto Burn DX, Is Keto Burn DX legit?, Keto Burn DX USA, Keto Burn DX Price, Keto Burn DX Amazon, Keto Burn DX Pills, Keto Burn DX ...
[RETRACTED] Keto Burn DX - (Works Or Hoax) Check Here All Improtant Keto Burn DX Details! MELT FAT FAST v1
[RETRACTED] Keto Burn DX - (Works Or Hoax) Check Here All Improtant Keto Burn DX Details! MELT FAT FAST v1
[RETRACTED]Keto Burn DX Review 2022 – Does it Really Work?Warning | Weight Loss Diet | Price | Get 2 Free Bottles! ➢ Product Name – Keto Burn DX ➢ Location – United States (USA) ➢...
[RETRACTED] Keto Burn DX - Keto Science ,Keto Burn DX Dual-Action Fat Burner Capsules, Weight Loss, Boost Metabolism, Increase Energy! v1
[RETRACTED] Keto Burn DX - Keto Science ,Keto Burn DX Dual-Action Fat Burner Capsules, Weight Loss, Boost Metabolism, Increase Energy! v1
[RETRACTED]Losing weight comes with various challenges and outcomes that are not performed by every person we come across. ➼ Order Now! Keto Burn DX Only From Official Website Chec...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
592 Medwatch: A Public Service Media Outlet Promoting Burn Prevention and Survivor Awareness
592 Medwatch: A Public Service Media Outlet Promoting Burn Prevention and Survivor Awareness
Abstract
Introduction
The American Burn Association estimates 486,000 burn injuries occur each year. Inability to receive specia...
85 QUALITY IMPROVEMENT INITIATIVE TO ASSESS FRAILTY AWARENESS AND USE CLINICAL FRAILTY SCALE AMONGST STAFF IN ACUTE AND PRIMARY CARE SITES
85 QUALITY IMPROVEMENT INITIATIVE TO ASSESS FRAILTY AWARENESS AND USE CLINICAL FRAILTY SCALE AMONGST STAFF IN ACUTE AND PRIMARY CARE SITES
Abstract
Background
Frailty describes a condition characterized by decreased physiological reserve and a decreased resistance to...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
Penyuluhan Penyakit Parkinson dan Skrining Frailty pada Penderita Parkinson di RSI Sultan Agung Semarang
Penyuluhan Penyakit Parkinson dan Skrining Frailty pada Penderita Parkinson di RSI Sultan Agung Semarang
Penyakit Parkinson merupakan kondisi neurodegeneratif yang progresif dan sering ditemukan pada populasi usia lanjut. Penyakit ini disertai dengan gejala motorik dan non-motorik yan...

